(4R)-3-[1-[1-(4,6-dimethylpyrimidine-5-carbonyl)-4-methylpiperidin-4-yl]piperidin-4-yl]-1-(oxan-4-ylmethyl)-4-phenylimidazolidin-2-one | 1108194-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (4R)-3-[1-[1-(4,6-dimethylpyrimidine-5-carbonyl)-4-methylpiperidin-4-yl]piperidin-4-yl]-1-(oxan-4-ylmethyl)-4-phenylimidazolidin-2-one
• CAS: 1108194-99-5
• 化学式: C₃₃H₄₆N₆O₃
• 分子量: 574.767
• InChiKey: LEIJVPCQIOHXMZ-LJAQVGFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  42
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (R)-3-(4'-methyl-[1,4'-bipiperidin]-4-yl)-4-phenyl-1-((tetrahydro-2H-pyran-4-yl)methyl)imidazolidin-2-one 、 4,6-二甲基嘧啶-5-甲酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以60%的产率得到(4R)-3-[1-[1-(4,6-dimethylpyrimidine-5-carbonyl)-4-methylpiperidin-4-yl]piperidin-4-yl]-1-(oxan-4-ylmethyl)-4-phenylimidazolidin-2-one
  参考文献：
  名称：

  Synthesis, SAR and evaluation of [1,4′]-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists

  摘要：

  Elaboration of our previously disclosed spiropiperidine template led to the development of a series of novel CCR5 antagonists. Results of SAR exploration and preliminary lead characterization are described. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.077

文献信息

• Heterocyclic antiviral compounds
  申请人：Gabriel Stephen Deems

  公开号：US20090028818A1

  公开（公告）日：2009-01-29

  This invention relates to piperidine derivatives of formula I wherein R 1 , R 2 , R 3 and R 4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPR.

  这项发明涉及式I的哌啶衍生物，其中R1、R2、R3和R4如本文所定义，在治疗各种疾病中有用，包括那些涉及CCR5受体调节的疾病。目前的衍生物可以治疗或预防的疾病包括HIV和遗传相关的逆转录病毒感染（以及由此导致的获得性免疫缺陷综合症，艾滋病），类风湿关节炎，固体器官移植排斥（移植物对宿主病），哮喘和慢性阻塞性肺疾病。
• [EN] HETEROCYCLIC ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX HÉTÉROCYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009013171A2

  公开（公告）日：2009-01-29

  This invention relates to piperidine derivatives of formula (I) wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPR.
• Synthesis, SAR and evaluation of [1,4′]-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists
  作者：David M. Rotstein、Stephen D. Gabriel、Nicole Manser、Lubov Filonova、Fernando Padilla、Surya Sankuratri、Changhua Ji、Andre deRosier、Marianna Dioszegi、Gabrielle Heilek、Andreas Jekle、Paul Weller、Pamela Berry

  DOI：10.1016/j.bmcl.2010.04.077

  日期：2010.6

  Elaboration of our previously disclosed spiropiperidine template led to the development of a series of novel CCR5 antagonists. Results of SAR exploration and preliminary lead characterization are described. (C) 2010 Elsevier Ltd. All rights reserved.